BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Revenue by Product

Fiscal year is April - March.

Fiscal Year	FY TTM	FY NaN	FY NaN	FY NaN	FY NaN
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Research and Development	72.00K
Research and Development Growth	-74.29%
Other	-
Other Growth	-
Drug Development	-
Drug Development Growth	-

Revenue by Geography

Fiscal year is April - March.

Fiscal Year	FY TTM	FY NaN	FY NaN	FY NaN	FY NaN
Period Ending	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019
Japan	72.00K
Japan Growth	-98.64%